NABI--Trouble Ahead? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NABI--Trouble Ahead?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Deca Row who wrote ()	3/27/1997 1:23:00 AM
From: Deca Row	of 12

To: jfrancis From: bourgeois MY REACTION TO TODAY'S ANNOUCEMENT. GOOD LUCK!!!! "Revenues for NABI are estimated to increase from $201 million in 1995 to over 4-5 million in 2000." The following is a quote about a year ago, looks like management is on track to me. David J. Gury has been Chairman of the Board, President and Chief Executive Officer since April 1992 and has been a Director of NABI since 1984. Since his tenure at his present positions, the price of the stock has risen from 2- area. Great record, as far as I'm concern. The recent(August 1995) merger with Univax along with the recent(January 1996) sale of 80 million of convertible subordinated notes, all INCREASE the success of the company as far as achieving its goals. That 80 million will help the company achieve a 21% from 4% increase in operating margins from its immunotherapeutics division. Notice how I used the words "recent" above, therefore, I see this as opportunities for the long term investor. The above mentioned division will provide NABI with strong earnings as soon as they can get their new manufacturing facility producing. Patience people, what's the ole cliche', ROME WAS NOT BUILT IN A DAY

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next